Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RNF217

Gene summary for RNF217

Gene summary.

Gene information	Species	Human
	Gene symbol	RNF217
	Gene ID	154214
	Gene name	ring finger protein 217
	Gene Alias	C6orf172
	Cytomap	6q22.31
	Gene Type	protein-coding
	GO ID	GO:0000209
	UniProtAcc	B3KVC8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
154214	RNF217	CCI_1	Human	Cervix	CC	1.90e-08	9.04e-01	0.528
154214	RNF217	CCI_2	Human	Cervix	CC	5.98e-10	1.31e+00	0.5249
154214	RNF217	CCI_3	Human	Cervix	CC	2.29e-08	8.47e-01	0.516
154214	RNF217	sample3	Human	Cervix	CC	2.24e-05	2.41e-01	0.1387
154214	RNF217	T3	Human	Cervix	CC	2.00e-05	2.48e-01	0.1389
154214	RNF217	LZE4T	Human	Esophagus	ESCC	9.15e-19	7.18e-01	0.0811
154214	RNF217	LZE7T	Human	Esophagus	ESCC	8.26e-06	3.41e-01	0.0667
154214	RNF217	LZE20T	Human	Esophagus	ESCC	5.09e-03	4.77e-02	0.0662
154214	RNF217	LZE24T	Human	Esophagus	ESCC	4.88e-04	5.12e-02	0.0596
154214	RNF217	LZE21T	Human	Esophagus	ESCC	4.17e-02	1.71e-01	0.0655
154214	RNF217	P2T-E	Human	Esophagus	ESCC	5.14e-11	6.89e-02	0.1177
154214	RNF217	P4T-E	Human	Esophagus	ESCC	5.63e-12	1.49e-01	0.1323
154214	RNF217	P5T-E	Human	Esophagus	ESCC	1.08e-10	1.32e-01	0.1327
154214	RNF217	P8T-E	Human	Esophagus	ESCC	1.73e-08	7.36e-02	0.0889
154214	RNF217	P9T-E	Human	Esophagus	ESCC	1.04e-04	1.72e-01	0.1131
154214	RNF217	P10T-E	Human	Esophagus	ESCC	6.99e-10	1.70e-01	0.116
154214	RNF217	P11T-E	Human	Esophagus	ESCC	1.13e-06	1.75e-01	0.1426
154214	RNF217	P12T-E	Human	Esophagus	ESCC	1.05e-13	1.54e-01	0.1122
154214	RNF217	P15T-E	Human	Esophagus	ESCC	1.05e-12	3.61e-01	0.1149
154214	RNF217	P16T-E	Human	Esophagus	ESCC	9.04e-03	2.68e-03	0.1153

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190336412	Liver	Cirrhotic	positive regulation of cellular protein catabolic process	80/4634	155/18723	5.04e-13	3.86e-11	80
GO:190305012	Liver	Cirrhotic	regulation of proteolysis involved in cellular protein catabolic process	103/4634	221/18723	1.14e-12	8.61e-11	103
GO:200005812	Liver	Cirrhotic	regulation of ubiquitin-dependent protein catabolic process	81/4634	164/18723	7.22e-12	4.92e-10	81
GO:006113612	Liver	Cirrhotic	regulation of proteasomal protein catabolic process	84/4634	187/18723	1.28e-09	5.56e-08	84
GO:190305211	Liver	Cirrhotic	positive regulation of proteolysis involved in cellular protein catabolic process	64/4634	133/18723	4.23e-09	1.70e-07	64
GO:003243412	Liver	Cirrhotic	regulation of proteasomal ubiquitin-dependent protein catabolic process	64/4634	134/18723	6.16e-09	2.40e-07	64
GO:200006012	Liver	Cirrhotic	positive regulation of ubiquitin-dependent protein catabolic process	52/4634	107/18723	7.75e-08	2.30e-06	52
GO:19018005	Liver	Cirrhotic	positive regulation of proteasomal protein catabolic process	54/4634	114/18723	1.30e-07	3.57e-06	54
GO:00324366	Liver	Cirrhotic	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	43/4634	90/18723	1.80e-06	3.40e-05	43
GO:000020911	Liver	Cirrhotic	protein polyubiquitination	89/4634	236/18723	6.09e-06	9.80e-05	89
GO:001049822	Liver	HCC	proteasomal protein catabolic process	351/7958	490/18723	6.92e-40	1.46e-36	351
GO:004316122	Liver	HCC	proteasome-mediated ubiquitin-dependent protein catabolic process	299/7958	412/18723	7.82e-36	8.27e-33	299
GO:000989622	Liver	HCC	positive regulation of catabolic process	335/7958	492/18723	3.83e-31	1.87e-28	335
GO:003133122	Liver	HCC	positive regulation of cellular catabolic process	295/7958	427/18723	3.20e-29	1.45e-26	295
GO:004217622	Liver	HCC	regulation of protein catabolic process	267/7958	391/18723	2.45e-25	7.38e-23	267
GO:190336222	Liver	HCC	regulation of cellular protein catabolic process	182/7958	255/18723	5.91e-21	8.52e-19	182
GO:004573222	Liver	HCC	positive regulation of protein catabolic process	163/7958	231/18723	4.00e-18	4.69e-16	163
GO:190305022	Liver	HCC	regulation of proteolysis involved in cellular protein catabolic process	157/7958	221/18723	5.93e-18	6.83e-16	157
GO:006113622	Liver	HCC	regulation of proteasomal protein catabolic process	134/7958	187/18723	5.03e-16	4.09e-14	134
GO:190336422	Liver	HCC	positive regulation of cellular protein catabolic process	115/7958	155/18723	9.30e-16	7.19e-14	115

Page: 1 2 3 4 5 6 7 8 9 10 11

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RNF217

SNV

Missense_Mutation

rs865840139

c.943G>A

p.Glu315Lys

p.E315K

Q8TC41

protein_coding

tolerated(0.07)

probably_damaging(0.999)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RNF217

insertion

Frame_Shift_Ins

novel

c.1240_1241insGATGCAGTGTTGATGTCTGTATGTGTTTGCGTAAGGCC

p.Glu414GlyfsTer39

p.E414Gfs*39

Q8TC41

protein_coding

TCGA-B6-A0I6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

RNF217

deletion

Frame_Shift_Del

novel

c.1623delN

p.Trp542GlyfsTer10

p.W542Gfs*10

Q8TC41

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

RNF217

SNV

Missense_Mutation

novel

c.346G>A

p.Asp116Asn

p.D116N

Q8TC41

protein_coding

deleterious_low_confidence(0.02)

benign(0.078)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

RNF217

SNV

Missense_Mutation

c.1277N>A

p.Cys426Tyr

p.C426Y

Q8TC41

protein_coding

deleterious(0.04)

probably_damaging(0.924)

TCGA-JW-A5VJ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

RNF217

SNV

Missense_Mutation

novel

c.601N>G

p.Arg201Gly

p.R201G

Q8TC41

protein_coding

tolerated_low_confidence(0.35)

benign(0.03)

TCGA-VS-A953-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

RNF217

insertion

Frame_Shift_Ins

novel

c.1587_1588insA

p.Gln532ThrfsTer16

p.Q532Tfs*16

Q8TC41

protein_coding

TCGA-EA-A3HU-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

RNF217

SNV

Missense_Mutation

c.1568N>G

p.Phe523Cys

p.F523C

Q8TC41

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-AA-A010-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Chemotherapy

folinic

RNF217

SNV

Missense_Mutation

rs778499520

c.1352N>A

p.Arg451Gln

p.R451Q

Q8TC41

protein_coding

tolerated(0.06)

probably_damaging(0.999)

TCGA-DM-A1D4-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

RNF217

SNV

Missense_Mutation

c.1528G>C

p.Ala510Pro

p.A510P

Q8TC41

protein_coding

deleterious(0.01)

possibly_damaging(0.896)

TCGA-AG-3592-01

Colorectum

rectum adenocarcinoma

Male

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1